Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data

被引:67
|
作者
Oitate, Masataka [1 ]
Masubuchi, Noriko [1 ]
Ito, Takashi [1 ]
Yabe, Yoshiyuki [1 ]
Karibe, Tsuyoshi [1 ]
Aoki, Takanori [1 ]
Murayama, Nobuyuki [1 ]
Kurihara, Atsushi [1 ]
Okudaira, Noriko [1 ]
Izumi, Takashi [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
关键词
monoclonal antibody; allometric scaling; prediction; clearance; distribution volume; pharmacokinetics; HUMAN DRUG CLEARANCE; DIMERIZATION INHIBITOR; PERTUZUMAB;
D O I
10.2133/dmpk.DMPK-11-RG-011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interspecies allometric scaling is a useful tool for calculating human pharmacokinetic (PK) parameters from data in animals. In this study, in order to determine the scaling exponent in a simple allometric equation that can predict human clearance (CL) and distribution volume at steady state (Vss) of monoclonal antibodies (mAbs) from monkey data alone, PK data of 24 mAbs were collected and analyzed according to the types of targeted antigens (soluble or membrane-bound antigens). Based on the observed PK data in humans (at clinical doses) and monkeys (at >1 mg/kg), where the PK is expected to be linear, the mean scaling exponents in the allometric equation for CL and Vss, respectively, against body weight were calculated to be 0.79 and 1.12 [95% confidence intervals (CIs): 0.69-0.89 and 0.96-1.28] for soluble antigens, and 0.96 and 1.00 (95% CIs: 0.83-1.09 and 0.87-1.13) for membrane-bound antigens. Using these exponents and monkey PK data (at >1 mg/kg) alone, both human CL and Vss of mAbs can be predicted with reasonable accuracy, i.e., within 2-fold of the observed values. Compared with traditional allometric scaling using PK data from three or more preclinical species, this approach is simple, quick, resource-saving, and useful in drug discovery and development.
引用
收藏
页码:423 / 430
页数:8
相关论文
共 50 条
  • [21] Quantitative prediction of human pharmacokinetics for duvortuxizumab from cynomolgus monkey data: a translational pharmacokinetic modeling approach
    Jiang, Xiling
    Li, Hua
    Nordstrom, Jeff
    Brown, Jennifer
    Liu, Liqin
    Johnson, Syd
    Alderson, Ralph
    Clemens, Pamela L.
    Shenton, Jacintha
    Khan, Imran
    Gardner, Olivia
    Sun, Yu-Nien
    Wang, Weirong
    CANCER RESEARCH, 2017, 77
  • [22] THERAPEUTIC USE OF HUMAN MONOCLONAL-ANTIBODIES
    CRAWFORD, DH
    HUEHNS, ER
    EPSTEIN, MA
    LANCET, 1983, 1 (8332): : 1040 - 1040
  • [23] A novel platform to produce human monoclonal antibodies The next generation of therapeutic human monoclonal antibodies discovery
    Duvall, Marcus
    Bradley, Norma
    Fiorini, Ryan N.
    MABS, 2011, 3 (02) : 203 - 208
  • [24] Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches
    Chen, Wenjun
    Wang, Lu
    Ruan, Zourong
    Lou, Honggang
    Jiang, Bo
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 113 (09) : 2915 - 2921
  • [25] RETROSPECTIVE ANALYSIS FOR PREDICTION OF HUMAN PHARMACOKINETICS USING CYNOMOLGUS MONKEY
    Aratsu, Yusuke
    Taniguchi, Toshio
    Nomura, Yukihiro
    Kogayu, Motohiro
    DRUG METABOLISM REVIEWS, 2015, 47 : 52 - 52
  • [26] Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
    Avery, Lindsay B.
    Wang, Mengmeng
    Kavosi, Mania S.
    Joyce, Alison
    Kurz, Jeffrey C.
    Fan, Yao-Yun
    Dowty, Martin E.
    Zhang, Minlei
    Zhang, Yiqun
    Cheng, Aili
    Hua, Fei
    Jones, Hannah M.
    Neubert, Hendrik
    Polzer, Robert J.
    O'Hara, Denise M.
    MABS, 2016, 8 (06) : 1064 - 1078
  • [27] Comparison of Different Methods for Predicting Pharmacokinetics of Monoclonal Antibodies in Human
    Singh , Renu
    Moreno, Maria
    Stanimirovic, Danica
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S36 - S37
  • [28] Isolation of human monoclonal antibodies from vaccinated individuals with a view to therapeutic application
    Elias, Sean
    Alanine, Dan
    Cherry, Catherine
    Rawlinson, Tom
    Silk, Sarah
    Labbe, Genevieve
    Mendelsohn, Simon
    Rijal, Pramila
    Townsend, Alain
    Draper, Simon
    HUMAN GENE THERAPY, 2015, 26 (09) : A23 - A23
  • [29] THERAPEUTIC HUMAN MONOCLONAL-ANTIBODIES - FROM THE LABORATORY TO CLINICAL-TRIALS
    ROUGER, P
    GOOSSENS, D
    KAROUBY, Y
    SALMON, C
    TRENDS IN BIOTECHNOLOGY, 1987, 5 (08) : 217 - 219
  • [30] PROSPECTS FOR THE THERAPEUTIC USE OF HUMAN MONOCLONAL-ANTIBODIES
    LARRICK, JW
    BOURLA, JM
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1986, 5 (05): : 379 - 393